| This study examined non-persistence with oral anticoagulants (OACs; apixaban, dabigatran, rivaroxaban, and warfarin) among patients with non-valvular atrial fibrillation (NVAF). OAC non-persistence among patients with NVAF has previously been associated with an increased risk of adverse events. |
| The risk of non-persistence varied among patients with NVAF; baseline characteristics and clinical events occurring after OAC initiation were significant predictors of non-persistence. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.